Zentalis Pharmaceuticals, Inc. $ZNTL Shares Sold by Voya Investment Management LLC

Voya Investment Management LLC cut its stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 69.7% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 17,282 shares of the company’s stock after selling 39,735 shares during the period. Voya Investment Management LLC’s holdings in Zentalis Pharmaceuticals were worth $27,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Cerity Partners LLC raised its holdings in Zentalis Pharmaceuticals by 58.7% in the first quarter. Cerity Partners LLC now owns 20,501 shares of the company’s stock valued at $33,000 after buying an additional 7,579 shares during the period. State of Wyoming raised its holdings in Zentalis Pharmaceuticals by 30.1% in the first quarter. State of Wyoming now owns 45,176 shares of the company’s stock valued at $72,000 after buying an additional 10,460 shares during the period. Deutsche Bank AG raised its holdings in Zentalis Pharmaceuticals by 34.1% in the fourth quarter. Deutsche Bank AG now owns 42,804 shares of the company’s stock valued at $130,000 after buying an additional 10,873 shares during the period. American Century Companies Inc. raised its holdings in Zentalis Pharmaceuticals by 46.2% in the first quarter. American Century Companies Inc. now owns 46,900 shares of the company’s stock valued at $75,000 after buying an additional 14,816 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in Zentalis Pharmaceuticals by 4.7% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 361,236 shares of the company’s stock valued at $574,000 after buying an additional 16,197 shares during the period.

Zentalis Pharmaceuticals Trading Up 2.0%

ZNTL stock opened at $1.54 on Thursday. Zentalis Pharmaceuticals, Inc. has a twelve month low of $1.01 and a twelve month high of $4.44. The company has a market capitalization of $111.10 million, a P/E ratio of -0.68 and a beta of 1.77. The firm has a 50 day simple moving average of $1.55 and a 200-day simple moving average of $1.44.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.19. On average, research analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently commented on ZNTL shares. Wall Street Zen upgraded shares of Zentalis Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Saturday, August 9th. HC Wainwright upgraded shares of Zentalis Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 7th. Finally, Wells Fargo & Company dropped their price objective on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Zentalis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.84.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.